• <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置首页>技术资料首页>行业动态>新品动态>Medtronic微创心脏瓣膜获FDA批准

    Medtronic微创心脏瓣膜获FDA批准

    Medtronic2010年1月26日 14:20 点击:2244

    美国美敦力公司(Medtronic, Inc.)
    美国食品和药物管理局(Food and Drug Administration)周一批准了Medtronic Inc's公司开发的微创心脏瓣膜,这种心脏瓣膜可通过导管进行置换,而不必进行外科手术。

      Medtronic上涨了2%。

    Medtronic新闻稿
    Medtronic Receives FDA Approval for First Replacement Heart Valve Implanted Without Surgery

     Medtronic Media Contacts:
    Jeff Warren, Investor Relations, 763-505-2696
    Joe McGrath, Public Relations, 707-591-7367
     

    Medtronic Receives FDA Approval for First Replacement Heart Valve Implanted Without Surgery

    Melody® Transcatheter Pulmonary Valve Offers Non-Surgical Valve Replacement Option for Congenital Heart Disease Patients

     

    MINNEAPOLIS – Jan. 25, 2009 – In a significant development for congenital heart disease patients, Medtronic, Inc. (NYSE: MDT), announced today that its Melody® Transcatheter Pulmonary Valve has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE). This innovative medical device is the first transcatheter heart valve to receive FDA approval.

    Delivered through a catheter requiring only a small incision, the Melody valve will benefit children and adults who are born with a malformation of their pulmonary valve, which is the valve between the heart and lungs. These patients often require open-heart surgery to restore effective blood flow to their lungs. Previously, the only way to repair or replace a failed pulmonary valve conduit was through additional surgeries. To date, more than 1,100 patients worldwide have received a Melody valve.

    “The Melody Transcatheter Pulmonary Valve is a significant technological breakthrough and offers a reprieve for many patients with congenital heart disease – many of whom are young and will require several heart surgeries over their lifetime,” said pediatric cardiologist Dr. William E. Hellenbrand of the NewYork-Presbyterian Morgan Stanley Children’s Hospital and Columbia University Medical Center.

    “The Melody valve gives patients with congenital heart disease a new, non-surgical approach to managing their disease.”

    “This novel technology will improve the lives of thousands of patients in the United States,” said Dr. John Liddicoat, vice president and general manager of the Structural Heart division, part of the CardioVascular business, at Medtronic. “Medtronic is leading the development of transcatheter therapies for heart valve disease. FDA approval of the Melody Transcatheter Pulmonary Valve is evidence of that leadership.”

    In October 2006, the Melody valve became the first transcatheter valve to receive regulatory approval anywhere in the world when it received the CE (Conformité Européenne) mark. It is now approved by the FDA for use in the United States under an HDE, a special regulatory approval for treatments intended for fewer than 4,000 U.S. patients per year. HDEs are granted for medical devices that have demonstrated reasonable safety and probable benefit, but not clinical effectiveness.

    Medtronic CardioVascular is committed to advancing the treatment of coronary, peripheral, aortic and structural heart disease through collaboration with leading clinicians, researchers and scientists worldwide.

    ABOUT MEDTRONIC
    Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.

    Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 24, 2009. Actual results may differ materially from anticipated results.


     

    (来源: Medtronic )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.67994619.com,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权?#20219;?#39064;,请在作品发表之日起一周内与本网联系,否则视为?#29260;?#30456;关权利。


    云南11选5技巧
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    乐透码 3d今天最新开机试机号 体彩可以网上购买吗 排三试机号今天查询 澳客app怎么用 足彩混合过关3串1规则 福建快3走势图开奖结果 捷报网球比分 澳門足球博彩即時賽果網站 全国体育彩票走势图 世青赛2019小组赛规则 ag真人试玩2000 江西快三的最大遗漏 福建十一选五走势图图一定牛 彩票实体店赚钱太难了